{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.4","upperLimit":"66.7","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Duration of OR was defined as the time from the first documentation of objective response (CR or PR) to the date of relapse.\n\nDuration of OR was censored on the date of last disease assessment or hematologic assessment for participants who have no documented relapse prior to data cut-off, dropout, or the initiation of alternative anticancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"MEDIAN","populationDescription":"The ITT population included participants who entered into the study and treated with moxetumomab pasudotox. Duration of OR was evaluated for participants who achieved OR per independent central review.","reportingStatus":"POSTED","timeFrame":"Prior to each treatment cycle, EOT (up to 24 weeks), monthly from the EOT assessment until the Day 181 assessment (only for CBC), at follow-up visits every 3 months for the next 24 months, and every 6 months thereafter (approximately 6 years)","title":"Duration of Objective Response Assessed by Blinded Independent Central Review","type":"SECONDARY","unitOfMeasure":"Months"}